Figure 1.

SVs Expressing the Tumor-Associated Antigen NYESO-1 Exhibit Enhanced Antitumor Efficacy In Vivo

(A) Treatment schema. BALB/c mice were injected i.p. (day −4) with CT26.Fluc.NYESO1 cells (7 × 10⁴) on the right side of the abdomen. Five days later (day 1), SV-LacZ or SV-NYESO1 was injected into the left side of the abdomen for 4 consecutive days for a total of 4 weeks. Tumor growth was measured once a week using noninvasive bioluminescence imaging. (B) Tumor growth curves are shown as fold changes relative to the luminescence on day 0 of the same mouse. Left graph, no treatment (control, n = 40). Middle graph, treated with SV-LacZ (SV-LacZ, n = 33). Right graph, treated with SV-NYESO1 (SV-NYESO1, n = 43). (C) Representative bioluminescence images of control and SV-treated mice bearing CT26.Fluc.NYESO1 tumors. (D) Survival plots of untreated (Control, n = 35) and SV-NYESO1- (n = 35) or SV-LacZ (n = 34)-treated mice. Statistical significance between SV-LacZ and SV-NYESO1 was determined with the Mantel-Cox text. Results are representatives of at least two independent experiments. ****p ≤ 0.0001.